Study of MK-3475 in Participants With Progressively Locally Advanced or Metastatic Carcinomas & Melanoma (P07990/MK-3475-001 AM2)
Official Title: Phase I Study of Single Agent MK-3475 in Patients With Progressively Locally Advanced or Metastatic Carcinomas & Melanoma
In Part A of this study, the dose of intravenous (IV) MK-3475 will be escalated to find the maximum tolerated dose (MTD) for participants with a histologically or cytologically confirmed diagnosis of any type of carcinoma or melanoma (MEL). Part B of the study will explore the efficacy of the drug at the MTD in participants with advanced or metastatic MEL.
Phase: Phase 1
Facility and Contact
Investigational Site 1
SP Clinical Trial Registry Call Center
Date Last Changed: October 21, 2011